Cancer Clinical Trial -Pionyr Immunotherapeutics-PY314-01

A Study of PY314 in Subjects With Advanced Solid Tumors

Drug

PY314, Combination Therapy: PY314 + Pembrolizumab

Phase

Phase I

Condition

Triple Negative Breast Estrogen Receptor/Progesterone Receptor Positive/ Her2 Negative Breast, Cervical, Colon, Endometrial, Fallopian, Gastric, Non-Small Cell Lung , Ovaian, Peritoneal, Renal, Vaginal, Vulvar

Keywords

CPI refractory